文献速递呼吸衰竭与机械通气儿科与产科急症

腺病毒35载体结核候选疫苗在活动性或既往肺结核成人中的安全性与免疫原性:一项随机试验

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01
一句话结论在HIV阴性、活动性(治疗1–4个月)或既往已治愈肺结核成人中,AERAS-402候选疫苗未出现临床显著肺部并发症,并诱导以Ag85B为主的强CD8+和中度CD4+ T细胞反应。

该II期随机、安慰剂对照、双盲剂量递增研究纳入72例HIV阴性南非成人,分为活动性肺结核(治疗1–4个月)和既往肺结核已治愈至少12个月两组。受试者接受三个剂量水平的AERAS-402(含三种分枝杆菌抗原的复制缺陷型腺病毒35载体疫苗)或安慰剂。安全性终点包括临床评估、流量容积曲线、一氧化碳弥散量、脉搏血氧饱和度、胸部X线和高分辨率胸部CT;免疫原性通过Ag85A、Ag85B和TB10.4肽池刺激后CD4和CD8 T细胞内细胞因子染色评估。结果显示未观察到归因于疫苗的临床状态(特别是急性类Koch现象反应)、肺功能或影像学的时间或剂量相关变化;注射部位反应为轻至中度;试纸法血尿在61例AERAS-402接种者中发生25例(41%),在11例安慰剂接种者中发生3例(27%),无肉眼血尿报告;AERAS-402在疫苗组诱导强CD8+和中度CD4+ T细胞反应,主要针对Ag85B。

要点

  • 在活动性(治疗1–4个月)或既往已治愈肺结核的HIV阴性成人中,AERAS-402未出现归因于疫苗的临床显著肺部并发症。
  • 未观察到归因于疫苗的临床状态(特别是急性类Koch现象反应)、肺功能或影像学的时间或剂量相关变化。
  • 注射部位反应为轻至中度;试纸法血尿在61例AERAS-402接种者中25例(41%)、11例安慰剂接种者中3例(27%),无肉眼血尿。
  • AERAS-402诱导强CD8+和中度CD4+ T细胞反应,两个疫苗组主要针对Ag85B。
  • 研究为II期随机、安慰剂对照、双盲剂量递增设计,共纳入72例HIV阴性南非成人。

适用人群与场景

  • HIV阴性成人南非队列(n=72),包括活动性肺结核(治疗1–4个月)或研究入组前至少12个月已治疗并被认为治愈的肺结核患者。

研究设计与关键结果

  • II期随机、安慰剂对照、双盲剂量递增研究,纳入72例HIV阴性南非成人,评估三个剂量水平的AERAS-402(含三种分枝杆菌抗原的复制缺陷型腺病毒35载体结核候选疫苗)与安慰剂。
  • 未观察到归因于疫苗的临床状态(特别是急性类Koch现象反应)、肺功能或影像学的时间或剂量相关变化。
  • 注射部位反应为轻至中度;试纸法血尿在61例AERAS-402接种者中25例(41%),在11例安慰剂接种者中3例(27%),无肉眼血尿报告。
  • AERAS-402诱导强CD8+和中度CD4+ T细胞反应,两个疫苗组主要针对Ag85B。

证据类型、等级与局限

  • 证据类型:II期随机、安慰剂对照、双盲剂量递增试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,AERAS-402候选结核疫苗用于当前或既往肺结核患者可诱导强免疫反应,且与临床显著肺部并发症无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Administration of tuberculosis (TB) vaccines in participants with previous or current pulmonary TB may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.

OBJECTIVES: To assess the safety and immunogenicity of three dose levels of the AERAS-402 live, replication-deficient adenovirus 35-vectored TB candidate vaccine, containing three mycobacterial antigens, in individuals with current or previous pulmonary TB.

METHODS: We performed a phase II randomized, placebo-controlled, double-blinded dose-escalation study in an HIV-negative adult South African cohort (n = 72) with active pulmonary TB (on treatment for 1-4 mo) or pulmonary TB treated at least 12 months before study entry and considered cured. Safety endpoints included clinical assessment, flow volume curves, diffusing capacity of the lung for carbon monoxide, pulse oximetry, chest radiograph, and high-resolution thoracic computerized tomography scans. Cytokine expression by CD4 and CD8 T cells, after stimulation with Ag85A, Ag85B, and TB10.4 peptide pools, was examined by intracellular cytokine staining.

MEASUREMENTS AND MAIN RESULTS: No apparent temporal or dose-related changes in clinical status (specifically acute, Koch phenomenon-like reactions), lung function, or radiology attributable to vaccine were observed. Injection site reactions were mild or moderate. Hematuria (by dipstick only) occurred in 25 (41%) of 61 AERAS-402 recipients and 3 (27%) of 11 placebo recipients, although no gross hematuria was reported. AERAS-402 induced robust CD8+ and moderate CD4+ T-cell responses, mainly to Ag85B in both vaccine groups.

CONCLUSIONS: Administration of the AERAS-402 candidate TB vaccine to participants with current or previous pulmonary TB induced a robust immune response and is not associated with clinically significant pulmonary complications. Clinical trial registered with www.clinicaltrials.gov (NCT 02414828) and in the South African National Clinical Trials Register ( www.sanctr.gov.za DOH 27-0808-2060).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. van Zyl-Smit RN, Esmail A, Bateman ME, et al. Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. Am J Respir Crit Care Med. 2017. PMID: 28060545. doi:10.1164/rccm.201603-0654OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。